The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance.
Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.
Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring […]» Read more
Being a rheumatologist and a patient with a rheumatic disease today: A perspective at the time of COVID-19.
Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.
Due to the frequent presence of interstitial lung disease and widespread use of immunosuppressive treatment, systemic sclerosis (SSc) patients may be considered at risk for a more severe disease course […]» Read more
Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus.
Systemic lupus erythematosus is a chronic remitting-relapsing autoimmune disease that affects multiple organ systems. In this article we discuss aspects in the management of lupus patients that are particularly relevant […]» Read more
Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: A perspective from China.
The impact of COVID-19 on rheumatology clinical practice and university teaching in Sydney, Australia.
American College of Rheumatology Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID-19 Pandemic.
To provide guidance to rheumatology providers on the management of adult rheumatic disease patients in the context of the COVID-19 pandemic.A task force, including 10 rheumatologists and 4 infectious diseases […]» Read more
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: ‘Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India’ by Gupta et al and ‘Antirheumatic agents in covid-19: is IL-6 the right target?’ by Capeechi et al.
[Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic].
In the current SARS-CoV-2 pandemic there are many questions regarding the safe treatment of patients with inflammatory rheumatic diseases. Many of these questions cannot yet be answered on an evidence-based […]» Read more
Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis.
The outbreak of COVID-19 in December 2019 in China has very quickly become a global health emergency with almost two million of infected patients worldwide. Along with the spread of […]» Read more
The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.
We appreciate our Italian colleagues’ interest in our editorial denoting the rheumatologist’s role in helping to diagnose and treat cytokine storm syndrome (CSS) in the setting of the Covid-19 panemic […]» Read more
In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is important for antibody production by B cells. Since its discovery more than 40 […]» Read more
On March 11th, 2020 the World Health Organization declared COVID-19 a global pandemic. The infection, transmitted by 2019 novel coronavirus (2019-nCov), was first discovered in December 2019, in Wuhan, Hubei […]» Read more
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries.
Stand Together and Deliver: Challenges and Opportunities for Rheumatology Education During the COVID19 Pandemic.
In a matter of weeks, the COVID19 crisis has totally upended clinical medicine and the practice of rheumatology. Our old ways of seeing patients in person, precepting fellows in clinic […]» Read more